We are monitoring the impact of COVID-19 on Antacids Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 2265
Share on
Share on

Global Antacids Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Drug Class, Formulation Type, Distribution Channel & Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 2265
Pages: 175

Global Antacids Market Size (2021 to 2026)

As per the report, the global antacids market size is predicted to be worth USD 20.53 billion by 2026 from USD 16.68 billion in 2021, growing at a CAGR of 4.24% during the forecast period.

Antacids are a group of medications that help neutralize the content of acid reflux in the stomach. It provides fast relief of heartburn, one of the main symptoms of gastroesophageal reflux digestion, and other symptoms are nausea, bloating, or belching. Antacids include magnesium carbonate, aluminum hydroxide, and magnesium trisilicate. Some people have reported allergic reactions to antacids. Antacids incorporate magnesium carbonate, aluminum hydroxide, and magnesium trisilicate. In addition, a few people have announced unfavorably susceptible responses to antacids.

MARKET DRIVERS:

The growing trend toward self-medication is increasing the demand for over-the-counter digestive products to treat gastrointestinal disorders, which is estimated to reflect the growth rate of the global antacids market.

Antacids are used to neutralize acidity and should, therefore, cause a dramatic increase in demand. However, according to a study conducted by the American Gastroenterological Association and published in the International Functional Foundation in February 2017, about one-third of the US population suffers from GERD.

The rise in the popularity of the counter drugs through digital advertisements and campaigns is lucrative to surge growth opportunities for the antacids market. The increasing prevalence to have treatment for gastrointestinal problems worldwide is creating chances for the market to grow. The geriatric population's rise propels the market's demand as acidity complications show a higher risk in aging people. The adoption of sedentary lifestyles also leads to several problems related to acidity. Growing demand for early diagnosis among individuals is also expanding the growth of the antacids market. Increasing focus on releasing quality drugs and a high production rate significantly influence the demand of the market. Rising disposable income in urban areas is leveraging the growth of the antacids market. Also, the growing priority for self-medication is elevating the growth rate of this market to the extent. Growing awareness of the early symptoms of gastrointestinal diseases is also fueling the demand for the antacids market.

MARKET RESTRAINTS:

Factors such as some side effects such as constipation, laxative effect, and allergic reactions are expected to restrain the growth rate of the global antacids market. Also, people suffering from certain medical conditions are prone to the adverse impacts that worsen their health because people with heart disease may have problems due to the high amount of sodium present in antacids.

Impact of COVID-19 on the global antacids market:

The novel coronavirus (COVID-19) pandemic has significantly impacted every business sector, including the healthcare sector. A negative impact was created by COVID 19 pandemic. People 65 Years and above are likely to deal with the acid retreat. The vagueness of the COVID 19 pandemic has made out stomachs agitates, and as of now, present proof indicates that extreme heartburn links up poor symptoms of the disease. The familiar form of heartburn medicine may surge the risk of developing COVID-19 in people. The proton-pump inhibitors are used for heartburn in people. As per the American Journal of Gastroenterology, doctors in the United States found people consuming proton-pump inhibitor (PPI) twice a day for acid reflux. Proton-pump inhibitors may threaten the gastric barrier to COVID 19 access and decrease the microbial diversity in the gut. The use of PPI is a threatening factor for testing positive with COVID 19. Patients who tested positive are observed to improve the disease outcomes with some proton-pump inhibitors. Despite the negative impact of COVID-19, the global antacids market is still expected to register a healthy growth rate during the forecast period.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Drug Class, Formulation Type, Distribution Channel, Disease Indications, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

 

This market research report on the global antacids market has been segmented and sub-segmented based on the drug class, formulation type, distribution channel, disease indications, end-user, and region.

Antacids Market – By Drug Class:

  • Proton Pump Inhibitors
  • H2 Antagonist
  • Pro-motility agents
  • Acid Neutralizers

The Proton pump inhibitors segment led the market in 2020, and the trend is anticipated to continue in the forecast period. However, the acid neutralizer segment emerges as a significant segment because of their occasional heartburn and availability range.

Antacids Market – By Formulation Type:

  • Tablet
  • Liquid
  • Powder

Based on the formulation type, the tablet segment held the majority of the share in the global market in 2020 and is anticipated to be the highest growing segment due to convenience in administration, low pricing, and mostly availability.

Antacids Market – By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Based on the distribution channel, the online pharmacies and drug stores, and pharmacies at the hospitals are expected to occupy the majority of the market share during the forecast period. The rising adoption of e-commerce and an increase in online stores boost the market's growth.

Antacids Market – By Disease Indications:

  • Cancer
  • Cardiovascular Disorders
  • Neurological Disorders
  • Immunological Disorders
  • Other Diseases

Antacids Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

The North American regional market held the leading share in the overall market due to the increasing number of gastro-oesophageal diseases and the growing geriatric population. Asia pacific stood second in contributing to the market share. China and India are the vital dominant regions due to improvements and healthcare services.

The antacids market in Europe is growing faster for the past few years and continues the same flow in the coming years. Germany is holding the highest share of the market when compared with other countries. Germany- Increasing capital income is a significant factor magnifying the demand of the market in this region. In addition, the rise in the consumption rate of drugs related to gastric problems increases the market's growth.

KEY MARKET PLAYERS:

Companies dominating the global antacids market are GlaxoSmithKline PLC, Abbott Laboratories, Pfizer, Inc., Sun Pharmaceuticals, and Dabur.

RECENT MARKET HAPPENINGS:

  • Sun Pharma launched an Ayurvedic digestive remedy called Pepmelt to compete with popular antacids such as ENO (Consumer Health), Digene (Abbott India), and Pudin Hara (Dabur), and Gelusil (Pfizer).
  • Lupin introduced the approved generic for Horizon Therapeutics PLC's Vimovo (naproxen/esomeprazole magnesium) delayed-release tablets in the United States in March 2020. The drug is a mixture of naproxen and esomeprazole magnesium, with naproxen being used for symptomatic treatment of arthritis and esomeprazole magnesium being used to reduce the risk of naproxen-associated stomach ulcers.
  • Dr. Reddy's Laboratories has reintroduced Famotidine Tablets USP, 10 mg and 20 mg, as an over-the-counter (OTC) medication in the United States in October 2020.
  • In January 2019, Dr. Reddy's laboratories released generic omeprazole delayed-release tablets to treat heartburn in the United States.
  • Perrigo released a new orally disintegrating omeprazole tablet for the treatment of persistent heartburn in April 2018.
  • Abbott launched the "NoSecondOpinion campaign" for Digene in September 2018, intending to encourage consumers to choose doctor's opinion over unwanted counsel.
  • GlaxoSmithKline (GSK) paid $13 billion for Novartis in March 2018. This deal would allow GSK's shareholders to obtain the full value of Novartis' consumer healthcare division. It would also assist GSK in expanding its medicinal range.
  • Dexilant (Dexlansoprazole), a proton pump inhibitor that employs dual delayed-release technology for patients with GERD was introduced by Takeda Pharmaceutical Company Limited in 2016.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Class                   

                                5.1.1 Introduction           

                                5.1.2 Proton Pump Inhibitors     

                                5.1.3 H2 Antagonist        

                                5.1.4 Pro-motility agents              

                                5.1.5 Acid Neutralizers  

                                5.1.6  Y-o-Y Growth Analysis, By Drug Class          

                                5.1.7  Market Attractiveness Analysis, Drug Class              

                                5.1.8  Market Share Analysis, By Drug Class         

                5.2 Formulation Type                    

                                5.2.1 Introduction           

                                5.2.2 Tablet        

                                5.2.3 Liquid        

                                5.2.4 Powder    

                                5.2.5 Y-o-Y Growth Analysis, By Formulation Type            

                                5.2.6 Market Attractiveness Analysis, By Formulation Type          

                                5.2.7 Market Share Analysis, By Formulation Type           

                5.3 Distribution Channel                               

                                5.3.1 Introduction           

                                5.3.2 Hospital Pharmacies            

                                5.3.3 Retail pharmacies 

                                5.3.4 Other        

                                5.3.5 Y-o-Y Growth Analysis, By Distribution Channel      

                                5.3.6  Market Attractiveness Analysis, By Distribution Channel   

                                5.3.7 Market Share Analysis, By Distribution Channel      

                5.4 Disease Indications  5.4.1 Introduction           

                                5.4.2 Cancer      

                                5.4.3 CardiovascularDisorders    

                                5.4.4 Neurological Disorders       

                                5.4.5 Immunological Disorders  

                                5.4.6 Other Diseases      

                                5.4.7 Y-o-Y Growth Analysis, By Disease Indications         

                                5.4.8  Market Attractiveness Analysis, By Disease Indications      

                                5.4.9  Market Share Analysis, By Disease Indications       

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Class

                                                6.1.3.3 By Formulation Type

                                                6.1.3.4 By Distribution Channel

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Class

                                                6.1.4.3 By Formulation Type

                                                6.1.4.4 By Distribution Channel

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Class

                                                6.1.5.3 By Formulation Type

                                                6.1.5.4 By Distribution Channel

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Glaxo Smith                

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Abbott Laboratories               

                8.3 Pfizer Inc                     

                8.4 Sun Pharmaceuticals                              

                8.5 Consumer Health                     

                8.6 Dabur                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Submarkets and Application along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Antacid Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  3. Global Proton Pump Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  4. Global H2 Antagonist Market, By Region, From 2021 to 2026 (USD Million)
  5. Global Acid Neutralizers Market, By Region, From 2021 to 2026 (USD Million)
  6. Global Pro-Motility Agents Market, By Region, From 2021 to 2026 (USD Million)
  7. Global Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  8. Global Tablet Market, By Region, From 2021 to 2026 (USD Million)
  9. Global Liquid Market, By Region, From 2021 to 2026 (USD Million)
  10. Global Powder Market, By Region, From 2021 to 2026 (USD Million)
  11. Global Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  12. Global Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  13. Global Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  14. Global Others Market, By Region, From 2021 to 2026 (USD Million)
  15. North America Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  16. North America Proton Pump Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  17. North America H2 Antagonist Market, By Region, From 2021 to 2026 (USD Million)
  18. North America Acid Neutralizers Market, By Region, From 2021 to 2026 (USD Million)
  19. North America Pro-Motility Agents Market, By Region, From 2021 to 2026 (USD Million)
  20. North America Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  21. North America Tablet Market, By Region, From 2021 to 2026 (USD Million)
  22. North America Liquid Market, By Region, From 2021 to 2026 (USD Million)
  23. North America Powder Market, By Region, From 2021 to 2026 (USD Million)
  24. North America Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  25. North America Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  26. North America Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  27. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  28. United States Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  29. United States Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  30. United States Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  31. Canada Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  32. Canada Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  33. Canada Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  34. Europe Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  35. Europe Proton Pump Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  36. Europe H2 Antagonist Market, By Region, From 2021 to 2026 (USD Million)
  37. Europe Acid Neutralizers Market, By Region, From 2021 to 2026 (USD Million)
  38. Europe Pro-Motility Agents Market, By Region, From 2021 to 2026 (USD Million)
  39. Europe Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  40. Europe Tablet Market, By Region, From 2021 to 2026 (USD Million)
  41. Europe Liquid Market, By Region, From 2021 to 2026 (USD Million)
  42. Europe Powder Market, By Region, From 2021 to 2026 (USD Million)
  43. Europe Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  44. Europe Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  45. Europe Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  46. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  47. U.K. Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  48. U.K. Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  49. U.K. Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  50. Germany Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  51. Germany Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  52. Germany Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  53. France Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  54. France Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  55. France Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  56. Italy Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  57. Italy Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  58. Italy Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  59. Spain Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  60. Spain Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  61. Spain Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  62. Asia Pacific Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  63. Asia Pacific Proton Pump Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  64. Asia Pacific H2 Antagonist Market, By Region, From 2021 to 2026 (USD Million)
  65. Asia Pacific Acid Neutralizers Market, By Region, From 2021 to 2026 (USD Million)
  66. Asia Pacific Pro-Motility Agents Market, By Region, From 2021 to 2026 (USD Million)
  67. Asia Pacific Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  68. Asia Pacific Tablet Market, By Region, From 2021 to 2026 (USD Million)
  69. Asia Pacific Liquid Market, By Region, From 2021 to 2026 (USD Million)
  70. Asia Pacific Powder Market, By Region, From 2021 to 2026 (USD Million)
  71. Asia Pacific Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  72. Asia Pacific Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  73. Asia Pacific Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  74. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  75. Japan Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  76. Japan Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  77. Japan Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  78. China Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  79. China Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  80. China Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  81. India Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  82. India Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  83. India Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  84. Australia Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  85. Australia Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  86. Australia Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  87. South Korea Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  88. South Korea Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  89. South Korea Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  90. Latin America Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  91. Latin America Proton Pump Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  92. Latin America H2 Antagonist Market, By Region, From 2021 to 2026 (USD Million)
  93. Latin America Acid Neutralizers Market, By Region, From 2021 to 2026 (USD Million)
  94. Latin America Pro-Motility Agents Market, By Region, From 2021 to 2026 (USD Million)
  95. Latin America Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  96. Latin America Tablet Market, By Region, From 2021 to 2026 (USD Million)
  97. Latin America Liquid Market, By Region, From 2021 to 2026 (USD Million)
  98. Latin America Powder Market, By Region, From 2021 to 2026 (USD Million)
  99. Latin America Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  100. Latin America Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  101. Latin America Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  102. Latin America Others Market, By Region, From 2021 to 2026 (USD Million)
  103. Brazil Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  104. Brazil Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  105. Brazil Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  106. Argentina Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  107. Argentina Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  108. Argentina Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  109. Mexico Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  110. Mexico Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  111. Mexico Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  112. Rest of Latin America Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  113. Rest of Latin America Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  114. Rest of Latin America Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  115. Middle East and Africa Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  116. Middle East and Africa Proton Pump Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  117. Middle East and Africa H2 Antagonist Market, By Region, From 2021 to 2026 (USD Million)
  118. Middle East and Africa Acid Neutralizers Market, By Region, From 2021 to 2026 (USD Million)
  119. Middle East and Africa Pro-Motility Agents Market, By Region, From 2021 to 2026 (USD Million)
  120. Middle East and Africa Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  121. Middle East and Africa Tablet Market, By Region, From 2021 to 2026 (USD Million)
  122. Middle East and Africa Liquid Market, By Region, From 2021 to 2026 (USD Million)
  123. Middle East and Africa Powder Market, By Region, From 2021 to 2026 (USD Million)
  124. Middle East and Africa Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  125. Middle East and Africa Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  126. Middle East and Africa Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  127. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Million)
  128. Middle East Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  129. Middle East Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  130. Middle East Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  131. Africa Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  132. Africa Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  133. Africa Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  134. North America Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  135. North America Proton Pump Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  136. North America H2 Antagonist Market, By Region, From 2021 to 2026 (USD Million)
  137. North America Acid Neutralizers Market, By Region, From 2021 to 2026 (USD Million)
  138. North America Pro-Motility Agents Market, By Region, From 2021 to 2026 (USD Million)
  139. North America Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  140. North America Tablet Market, By Region, From 2021 to 2026 (USD Million)
  141. North America Liquid Market, By Region, From 2021 to 2026 (USD Million)
  142. North America Powder Market, By Region, From 2021 to 2026 (USD Million)
  143. North America Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  144. North America Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  145. North America Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  146. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  147. United States Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  148. United States Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  149. United States Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  150. Canada Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  151. Canada Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  152. Canada Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  153. Europe Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  154. Europe Proton Pump Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  155. Europe H2 Antagonist Market, By Region, From 2021 to 2026 (USD Million)
  156. Europe Acid Neutralizers Market, By Region, From 2021 to 2026 (USD Million)
  157. Europe Pro-Motility Agents Market, By Region, From 2021 to 2026 (USD Million)
  158. Europe Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  159. Europe Tablet Market, By Region, From 2021 to 2026 (USD Million)
  160. Europe Liquid Market, By Region, From 2021 to 2026 (USD Million)
  161. Europe Powder Market, By Region, From 2021 to 2026 (USD Million)
  162. Europe Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  163. Europe Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  164. Europe Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  165. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  166. U.K. Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  167. U.K. Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  168. U.K. Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  169. Germany Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  170. Germany Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  171. Germany Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  172. France Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  173. France Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  174. France Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  175. Italy Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  176. Italy Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  177. Italy Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  178. Spain Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  179. Spain Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  180. Spain Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  181. Asia Pacific Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  182. Asia Pacific Proton Pump Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  183. Asia Pacific H2 Antagonist Market, By Region, From 2021 to 2026 (USD Million)
  184. Asia Pacific Acid Neutralizers Market, By Region, From 2021 to 2026 (USD Million)
  185. Asia Pacific Pro-Motility Agents Market, By Region, From 2021 to 2026 (USD Million)
  186. Asia Pacific Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  187. Asia Pacific Tablet Market, By Region, From 2021 to 2026 (USD Million)
  188. Asia Pacific Liquid Market, By Region, From 2021 to 2026 (USD Million)
  189. Asia Pacific Powder Market, By Region, From 2021 to 2026 (USD Million)
  190. Asia Pacific Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  191. Asia Pacific Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  192. Asia Pacific Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  193. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  194. Japan Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  195. Japan Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  196. Japan Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  197. China Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  198. China Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  199. China Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  200. India Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  201. India Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  202. India Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  203. Australia Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  204. Australia Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  205. Australia Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  206. South Korea Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  207. South Korea Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  208. South Korea Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  209. Latin America Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  210. Latin America Proton Pump Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  211. Latin America H2 Antagonist Market, By Region, From 2021 to 2026 (USD Million)
  212. Latin America Acid Neutralizers Market, By Region, From 2021 to 2026 (USD Million)
  213. Latin America Pro-Motility Agents Market, By Region, From 2021 to 2026 (USD Million)
  214. Latin America Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  215. Latin America Tablet Market, By Region, From 2021 to 2026 (USD Million)
  216. Latin America Liquid Market, By Region, From 2021 to 2026 (USD Million)
  217. Latin America Powder Market, By Region, From 2021 to 2026 (USD Million)
  218. Latin America Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  219. Latin America Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  220. Latin America Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  221. Latin America Others Market, By Region, From 2021 to 2026 (USD Million)
  222. Brazil Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  223. Brazil Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  224. Brazil Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  225. Argentina Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  226. Argentina Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  227. Argentina Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  228. Mexico Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  229. Mexico Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  230. Mexico Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  231. Rest of Latin America Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  232. Rest of Latin America Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  233. Rest of Latin America Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  234. Middle East and Africa Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  235. Middle East and Africa Proton Pump Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  236. Middle East and Africa H2 Antagonist Market, By Region, From 2021 to 2026 (USD Million)
  237. Middle East and Africa Acid Neutralizers Market, By Region, From 2021 to 2026 (USD Million)
  238. Middle East and Africa Pro-Motility Agents Market, By Region, From 2021 to 2026 (USD Million)
  239. Middle East and Africa Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  240. Middle East and Africa Tablet Market, By Region, From 2021 to 2026 (USD Million)
  241. Middle East and Africa Liquid Market, By Region, From 2021 to 2026 (USD Million)
  242. Middle East and Africa Powder Market, By Region, From 2021 to 2026 (USD Million)
  243. Middle East and Africa Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  244. Middle East and Africa Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  245. Middle East and Africa Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Million)
  246. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Million)
  247. Middle East Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  248. Middle East Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  249. Middle East Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)
  250. Africa Antacid Market, By Drug Class, From 2021 to 2026 (USD Million)
  251. Africa Antacid Market, By Formulation type, From 2021 to 2026 (USD Million)
  252. Africa Antacid Market, By Distribution Channel, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample